Free Trial
NASDAQ:BGLC

BioNexus Gene Lab (BGLC) Stock Price, News & Analysis

BioNexus Gene Lab logo
$5.20 +0.01 (+0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$5.09 -0.11 (-2.12%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioNexus Gene Lab Stock (NASDAQ:BGLC)

Advanced

Key Stats

Today's Range
$5.11
$5.25
50-Day Range
$4.36
$6.00
52-Week Range
$2.01
$15.60
Volume
26,988 shs
Average Volume
967,235 shs
Market Capitalization
$9.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

BioNexus Gene Lab Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

BGLC MarketRank™: 

BioNexus Gene Lab scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Book Value per Share Ratio

    BioNexus Gene Lab has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.28% of the float of BioNexus Gene Lab has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNexus Gene Lab has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioNexus Gene Lab has recently decreased by 73.49%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioNexus Gene Lab does not currently pay a dividend.

  • Dividend Growth

    BioNexus Gene Lab does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.28% of the float of BioNexus Gene Lab has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNexus Gene Lab has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioNexus Gene Lab has recently decreased by 73.49%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioNexus Gene Lab has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for BioNexus Gene Lab this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNexus Gene Lab insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.70% of the stock of BioNexus Gene Lab is held by insiders.

  • Percentage Held by Institutions

    Only 18.85% of the stock of BioNexus Gene Lab is held by institutions.

  • Read more about BioNexus Gene Lab's insider trading history.
Receive BGLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNexus Gene Lab and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BGLC Stock News Headlines

Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
BioNexus Gene Lab Corp. (BGLC) - Yahoo Finance
See More Headlines

BGLC Stock Analysis - Frequently Asked Questions

BioNexus Gene Lab's stock was trading at $2.7970 at the beginning of 2025. Since then, BGLC stock has increased by 85.4% and is now trading at $5.1860.

BioNexus Gene Lab Corp. (NASDAQ:BGLC) released its quarterly earnings data on Monday, August, 18th. The company reported ($0.34) earnings per share for the quarter. The firm earned $2.26 million during the quarter. BioNexus Gene Lab had a negative trailing twelve-month return on equity of 35.54% and a negative net margin of 30.70%.

BioNexus Gene Lab's stock reverse split before market open on Monday, April 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, April 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

BioNexus Gene Lab (BGLC) raised $5 million in an initial public offering on Thursday, July 20th 2023. The company issued 1,300,000 shares at a price of $4.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO.

Shares of BGLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNexus Gene Lab investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
8/18/2025
Today
10/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:BGLC
CIK
1737523
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.60 million
Net Margins
-30.70%
Pretax Margin
-31.47%
Return on Equity
-35.54%
Return on Assets
-29.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.63
Quick Ratio
2.94

Sales & Book Value

Annual Sales
$9.51 million
Price / Sales
0.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.63 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
1,800,000
Free Float
1,784,000
Market Cap
$9.36 million
Optionable
Not Optionable
Beta
5.20
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:BGLC) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners